Statistik Asas
| LEI | 549300PNZ0UEJVKN1618 |
| CIK | 1685316 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ObsEva SA
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| April 26, 2023 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-37993 OBSEVA SA (Exact name of registrant as specified in its ch |
|
| April 17, 2023 |
OBSV / ObsEva SA. / Loumaye Ernest - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ObsEva SA (Name of Issuer) Common Shares, par value CHF 1/13 per share (Title of Class of Securities) H5861P103 (CUSIP Number) Ernest Loumaye c/o ObsEva SA Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland +41 22 552 38 40 (Name, Address |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2023 OBSEVA SA (Exact name of registrant as specified in its Charter) Switzerland 001-37993 Not Applicable (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 31, 2023 |
List of subsidiaries of the Registrant Exhibit 21.1 ObsEva SA List of Subsidiaries Subsidiary Jurisdiction ObsEva USA, Inc. Delaware ObsEva Ireland Limited Ireland ObsEva Europe B.V. The Netherlands |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37 |
|
| March 31, 2023 |
Exhibit 10.20 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Execution Version IP ACQUISITION AGREEMENT This IP ACQUISITION AGREEMENT (this “Agreement”), dated as of November 21, 2022 (the “Effective Date”), is made by and between |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 POS AM 1 d492940dposam.htm POS AM As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. 333-268723 Registration No. 333-266492 Registration No. 333-262820 Registration No. 333-260974 Registration No. 333-233069 Registration No. 333-222820 Registration No. 333-221462 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT TO |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 POS AM As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 POS AM 1 d492940dposam.htm POS AM As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. 333-268723 Registration No. 333-266492 Registration No. 333-262820 Registration No. 333-260974 Registration No. 333-233069 Registration No. 333-222820 Registration No. 333-221462 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT TO |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 S-8 POS As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-37993 OBSEVA SA The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Chemin des Aulx |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 OBSEVA SA (Exact name of registrant as specified in its Charter) Switzerland 001-37993 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2023 OBSEVA SA (Exact name of registrant as specified in its Charter) Switzerland 001-37993 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 15, 2023 |
EX-99.1 Exhibit 99.1 ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies f |
|
| March 13, 2023 |
EX-99.1 Exhibit 99.1 ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Ernest Loumaye, |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 OBSEVA SA (Exact name of registrant as specified in its Charter) Switzerland 001-37993 Not Applicable (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 OBSEVA SA (Exact name of registrant as specified in its Charter) Switzerland 001-37993 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 OBSEVA SA (Exact name of registrant as specified in its Charter) Switzerland 001-37993 Not Applicable (State or other jurisdiction of incorporation) (Commission File |
|
| February 24, 2023 |
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland EX-99.1 Exhibit 99.1 CONFIDENTIAL ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced a strategic reorganizati |
|
| February 14, 2023 |
OBSV / Obseva SA / Loumaye Ernest - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5) ObsEva SA (Name of Issuer) Common Shares, par value CHF 1/13 per share (Title of Class of Securities) H5861P103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 6, 2023 |
OBSV / Obseva SA / Sofinnova Venture Partners VIII, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* ObsEva SA (Name of Issuer) Common Shares, par value CHF 1/13 per share (Title of Class of Securities) H5861P103 (CUSIP Number) Nathalie Auber Sofinnova Investments, In |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 OBSEVA SA (Exact name of registrant as specified in its Charter) Switzerland 001-37993 Not Applicable (State or other jurisdiction of incorporation) (Commission File N |
|
| December 19, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal |
|
| December 19, 2022 |
ObsEva Announces Dismissal of Moratorium Proceedings EX-99.1 Exhibit 99.1 ObsEva Announces Dismissal of Moratorium Proceedings Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the competent court in Geneva, Switzerland has granted the Com |
|
| December 14, 2022 |
EX-99.1 Exhibit 99.1 ObsEva Evidences Compliance with Nasdaq’s Stockholder’s Equity Rule and Announces Moratorium Dismissal Request Filing Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced today an |
|
| December 14, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal |
|
| December 9, 2022 |
As filed with the Securities and Exchange Commission on December 9, 2022 Table of Contents As filed with the Securities and Exchange Commission on December 9, 2022 Registration No. |
|
| December 9, 2022 |
ObsEva SA Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland CORRESP 1 filename1.htm ObsEva SA Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland December 9, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: ObsEva SA Registration Statement on Form F-3 Filed December 9, 2022 File No. 333-268723 Acceleration Request Requested Date: December 12, 2 |
|
| December 9, 2022 |
EX-FILING FEES 7 d358208dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) ObsEva SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offerin |
|
| December 9, 2022 |
Articles of Association of the Registrant Exhibit 4.1 STATUTS ARTICLES OF ASSOCIATION DE OF ObsEva SA (ObsEva Ltd) (ObsEva AG) ObsEva SA (ObsEva Ltd) (ObsEva AG) TITRE I: RAISON SOCIALE - SIEGE - BUT ? DUREE TITLE I: CORPORATE NAME - REGISTERED OFFICE - PURPOSE - DURATION Article 1: Raison sociale Article 1: Corporate Name Il existe sous la raison sociale There exists under the name ObsEva SA (ObsEva Ltd) (ObsEva AG) ObsEva SA (ObsEva Ltd |
|
| December 9, 2022 |
Exhibit 4.2 OBSEVA SA Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Section 2.03 Denomina |
|
| December 9, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal |
|
| December 9, 2022 |
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares Exhibit 99.1 ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? December 9, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women?s health, announced today that its board of directors approved on December 8 |
|
| December 1, 2022 |
Obseva SA Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a biopharmaceutical company focused on the development of novel therapies to improve women?s reproductive health. We are advancing a development program focused on improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. On July 27, 2022, |
|
| December 1, 2022 |
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update Exhibit 99.3 ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? December 1, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN) (?ObsEva? or the ?Company?), a biopharmaceutical company developing novel therapies for women?s health, today reported financial results for the third quart |
|
| December 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| December 1, 2022 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month and nine-month periods ended September 30, 2022 3 Unaudited Condensed Consolidated Statement of Cash Flows for the nine-month perio |
|
| November 22, 2022 |
ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million EX-99.2 Exhibit 99.2 ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million • Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 million • The sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss moratorium |
|
| November 22, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal |
|
| November 22, 2022 |
CONSENT AND AMENDMENT AGREEMENT EX-99.1 Exhibit 99.1 Execution Version CONSENT AND AMENDMENT AGREEMENT This Consent and Amendment Agreement (this “Consent”), dated as of November 21, 2022, is entered into between ObsEva SA, a Swiss stock corporation (the “Company”), and JGB (Cayman) Port Ellen Ltd., (the “Holder”) (each a “Party” and together, the “Parties”). WHEREAS, reference is made to that certain IP Acquisition Agreement, b |
|
| October 26, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal e |
|
| October 26, 2022 |
AMENDMENT AND FORBEARANCE EXTENSION AGREEMENT Exhibit 99.2 AMENDMENT AND FORBEARANCE EXTENSION AGREEMENT This Amendment and Forbearance Extension Agreement (the ?Agreement?), dated as of October 26, 2022 (the ?Effective Date?), is made by and between JGB (Cayman) Port Ellen Ltd., in its capacity as Holder (the ?Holder?), ObsEva SA, a Swiss stock corporation (the ?Company?) and each of ObsEva USA Inc., ObsEva Ireland Ltd., and ObsEva Europe B. |
|
| October 26, 2022 |
ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings Exhibit 99.1 ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings ? Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7 million of accounts payable assigned to date ? Company extends forbearance agreement with JGB throug |
|
| October 13, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal e |
|
| October 13, 2022 |
ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China Exhibit 99.1 ObsEva Announces IND Approval for Yuyuan Bioscience?s Phase 1 Clinical Trial of Nolasiban in China Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? October 13, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women?s health, today announced that Yuyuan Bioscience?s (Yuyuan) IND application |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exe |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address o |
|
| September 13, 2022 |
ObsEva Announces Progress on Restructuring Initiatives Exhibit 99.1 ObsEva Announces Progress on Restructuring Initiatives ? $7.6 million annual savings expected via reduction-in-force currently underway ? $6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd., including $1.7 million of accounts payable assigned to date. Additional assignments are expected in the coming weeks. ? Company |
|
| September 13, 2022 |
Unaudited Condensed Consolidated Financial Statements. Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended June 30, 2022 3 Unaudited Condensed Consolidated Statement of Cash Flows for the six-month period ended June |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execut |
|
| August 22, 2022 |
ObsEva Receives Nasdaq Non-Compliance Notice Exhibit 99.1 ObsEva Receives Nasdaq Non-Compliance Notice Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA ? August 22, 2022 ? ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing novel therapies to improve women?s reproductive health, today announced that on August 19, 2022 it received a notification letter from The Na |
|
| August 17, 2022 |
Obseva SA Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a biopharmaceutical company focused on the development of novel therapies to improve women?s reproductive health. We are advancing a pipeline of orally-administered innovative new chemical entities, or NCEs, for the treatment of symptoms associated with preterm labor and imp |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execut |
|
| August 17, 2022 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended June 30, 2022 3 Unaudited Condensed Consolidated Statement of Cash Flows for the six-month period ended June |
|
| August 17, 2022 |
ObsEva Files Second Quarter 2022 Financial Statements Exhibit 99.3 ObsEva Files Second Quarter 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA ? August 17, 2022 ? ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women?s reproductive health, today published its Second Quarter 2022 Financial Statem |
|
| August 3, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) ObsEva SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Equity Common Shares, par value CHF 1/13 per share 457(c) 20,326,980 0. |
|
| August 3, 2022 |
As filed with the Securities and Exchange Commission on August 3, 2022 As filed with the Securities and Exchange Commission on August 3, 2022 Registration No. |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execut |
|
| August 1, 2022 |
AMENDMENT AND FORBEARANCE AGREEMENT Exhibit 99.2 AMENDMENT AND FORBEARANCE AGREEMENT This Amendment and Forbearance Agreement (the ?Agreement?), dated as of July 31, 2022, is made by and between JGB (Cayman) Port Ellen Ltd., in its capacity as Holder (the ?Holder?), ObsEva SA, a Swiss stock corporation (the ?Company?) and each of ObsEva USA Inc., ObsEva Ireland Ltd., and ObsEva Europe B.V., as subsidiary guarantors (collectively, th |
|
| August 1, 2022 |
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing Exhibit 99.1 ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? August 1, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women?s health, today announced the early retirement of $31 million in debt that was part of amounts owed |
|
| July 29, 2022 |
ObsEva Announces Management Change Exhibit 99.1 CONFIDENTIAL AND UNDER EMBARGO ObsEva Announces Management Change Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? July 29, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women?s health, today announced the resignation of Jean-Pierre Gotteland, Chief Scientific Officer and Head of Researc |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executiv |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executiv |
|
| July 27, 2022 |
ObsEva Announces Corporate Updates Exhibit 99.1 ObsEva Announces Corporate Updates Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? July 27, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women?s health, today announced that it plans to initiate a corporate restructuring and refocus the Company?s development and commercialization strat |
|
| July 27, 2022 |
ObsEva Announces Corporate Updates Exhibit 99.2 ObsEva Announces Corporate Updates Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? July 27, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women?s health, today announced that Fabien de Ladonchamps, Chief Administrative Officer, is stepping down from the Company?s Executive Committee, ef |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executiv |
|
| June 28, 2022 |
Exhibit 99.1 ObsEva Announces UK MHRA Marketing Authorization for Yselty? (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids -Yselty? (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty?; ObsEva to receive royalties on commercial sales, as well as devel |
|
| June 17, 2022 |
Exhibit 99.1 ObsEva Announces European Commission Marketing Authorization for Yselty? (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids -Yselty? (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty?; ObsEva to receive royalties on commercial sales, as w |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executiv |
|
| May 27, 2022 |
ObsEva Announces Corporate Updates Exhibit 99.1 ObsEva Announces Corporate Updates Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? May 27, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women?s health, announced today that it has entered into a waiver and amendment agreement (Amendment Agreement) with respect to it |
|
| May 27, 2022 |
WAIVER AND AMENDMENT AGREEMENT Exhibit 99.2 WAIVER AND AMENDMENT AGREEMENT This Wavier and Amendment Agreement (the ?Agreement?), dated as of May 27, 2022, is made by and between JGB (Cayman) Port Ellen Ltd., in its capacity as Holder, ObsEva SA, a Swiss stock corporation (the ?Company?) and each of ObsEva USA Inc., ObsEva Ireland Ltd., and ObsEva Europe B.V., as subsidiary guarantors (collectively, the ?Subsidiary Guarantors?, |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executive |
|
| May 19, 2022 |
6-K 1 d351110d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Addre |
|
| May 19, 2022 |
Exhibit 99.1 ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland ? May 19, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women?s health, today announced that share |
|
| May 17, 2022 |
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update EX-99.3 4 obsv-ex9936.htm EX-99.3 Exhibit 99.3 ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update -Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy |
|
| May 17, 2022 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month ended March 31, 2022 3 Unaudited Condensed Consolidated Statement of Cash Flows for the three-month period ended March 31, 2022 4 Unaud |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executive |
|
| May 17, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a biopharmaceutical company focused on the development and commercialization of novel therapies to improve women?s reproductive health. We are advancing a pipeline of orally-administered innovative new chemical entities, or NCEs, for the treatment of symptoms associated with uterine f |
|
| May 2, 2022 |
6-K 1 d232839d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland ( |
|
| May 2, 2022 |
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer Exhibit 99.1 ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? May 2, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women?s health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Off |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executi |
|
| April 25, 2022 |
Exhibit 99.1 ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? April 25, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women?s health, today announc |
|
| April 7, 2022 |
ObsEva Annual General Meeting 2022 EX-99.1 2 d333284dex991.htm EX-99.1 Exhibit 99.1 ObsEva Annual General Meeting 2022 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – April 7, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today published the invitation to its 202 |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executi |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executi |
|
| March 31, 2022 |
Exhibit 99.1 ObsEva Annual Report 2021 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA ? March 31, 2022 ? ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women?s reproductive health, today published its Annual Report 2021 to Shareholders. The Annual Report 2021 to Sha |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executi |
|
| March 22, 2022 |
Exhibit 99.1 ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain ? Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses aft |
|
| March 10, 2022 |
Exhibit 4.4 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Exclusive License Agreement, by and between the Registrant and Kissei Pharmaceutical Co., Ltd., dated as of November 19, 2015, as amended pursuant to amendment agreements dated |
|
| March 10, 2022 |
Exhibit 4.13 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT (EBOPIPRANT) This License Agreement (the ?Agreement?) is entered into as of July 26, 2021 (the ?Effective Date?), by and between ObsEva SA, having an address |
|
| March 10, 2022 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of ObsEva SA (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Will Brown, Chief F |
|
| March 10, 2022 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Brian O’Callaghan, certify that: 1. I have reviewed this annual report on Form 20-F of ObsEva SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit |
|
| March 10, 2022 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of ObsEva SA (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian O’Callaghan, |
|
| March 10, 2022 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Will Brown, certify that: 1. I have reviewed this annual report on Form 20-F of ObsEva SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to sta |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 10, 2022 |
6-K 1 d315321d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Add |
|
| March 10, 2022 |
License Agreement between the Registrant and Theramex HQ UK Limited, dated as of February 10, 2022. Exhibit 4.14 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AGREEMENT between OBSEVA SA and THERAMEX HQ UK Limited Dated as of 10 February 2022 LICENSE AGREEMENT This License and Distribution Agreement (the ?Agreement?) is made |
|
| March 10, 2022 |
Consent of PricewaterhouseCoopers SA Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-233069, 333-260974, 333-221462 and 333-262820) and Form S-8 (No. 333-249457, 333-231629, 333-216170, and 333-263234) of ObsEva SA of our report dated March 10, 2022 relating to the financial statements, which appears in this F |
|
| March 10, 2022 |
Exhibit 99.1 ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update -Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Entered strategic licensing agreement with Theramex for comm |
|
| March 3, 2022 |
424B7 1 d309373d424b7.htm 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-262820 PROSPECTUS Up to 7,344,017 Common Shares This prospectus relates to the resale from time to time of up to 7,344,017 common shares of ObsEva SA, or the Company, by the selling shareholders, including their transferees, pledgees or donees, or their respective successors. We are registering |
|
| March 2, 2022 |
Filing Fee Table (filed herewith). EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 ObsEva SA Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Shares, CHF 0. |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 2, 2022 S-8 1 d289489ds8.htm S-8 As filed with the Securities and Exchange Commission on March 2, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ObsEva SA (Exact name of Registrant as specified in its charter) Switzerland Not applicable (State or other jurisdiction of Incorporation or organ |
|
| February 28, 2022 |
OBSV / Obseva SA / Sofinnova Venture Partners VIII, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* ObsEva SA (Name of Issuer) Common Stock, par value CHF 0.0769 per share (Title of Class of Securities) H5861P103 (CUSIP Number) Nathalie Auber Sofinnova Investments, I |
|
| February 25, 2022 |
As filed with the Securities and Exchange Commission on February 25, 2022 As filed with the Securities and Exchange Commission on February 25, 2022 Registration No. |
|
| February 25, 2022 |
Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland February 25, 2022 VIA EDGAR U. |
|
| February 17, 2022 |
Powers of Attorney (included on the signature page). Table of Contents As filed with the Securities and Exchange Commission on February 17, 2022 Registration No. |
|
| February 17, 2022 |
Exhibit 4.1 STATUTS DE ObsEva SA (ObsEva Ltd) (ObsEva AG) ARTICLES OF ASSOCIATION OF ObsEva SA (ObsEva Ltd) (ObsEva AG) TITRE I: RAISON SOCIALE - SIEGE - BUT ? DUREE TITLE I: CORPORATE NAME - REGISTERED OFFICE - PURPOSE - DURATION Article 1: Raison sociale Article 1: Corporate Name Il existe sous la raison sociale ObsEva SA (ObsEva Ltd) (ObsEva AG) une soci?t? anonyme qui est r?gie par les pr?sent |
|
| February 17, 2022 |
EX-FILING FEES 5 d309373dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) ObsEva SA (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Reg |
|
| February 14, 2022 |
OBSV / Obseva SA / Loumaye Ernest - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) ObsEva SA (Name of Issuer) Common Shares, par value CHF 1/13 per share (Title of Class of Securities) H5861P103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| February 10, 2022 |
Exhibit 99.1 ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix - Partnership leverages Theramex?s leading women?s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside of the U.S., Canada and Asia - - Linzagolix is an oral GnRH antagonist in development for th |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| February 4, 2022 |
Exhibit 99.1 ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? February 4, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women?s health, today |
|
| February 1, 2022 |
ObsEva Appoints Katja Buhrer as Chief Strategy Officer EX-99.1 2 d298410dex991.htm EX-99.1 Exhibit 99.1 ObsEva Appoints Katja Buhrer as Chief Strategy Officer Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 1, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Katja Buhrer as Chi |
|
| February 1, 2022 |
6-K 1 d298410d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland ( |
|
| January 28, 2022 |
AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT EX-99.3 4 d267124dex993.htm EX-99.3 Exhibit 99.3 AMENDED AND RESTATED SECURITIES PURCHASE AGREEMENT This Amended and Restated Securities Purchase Agreement (this “Agreement”) is deemed to be dated as of October 12, 2021, between ObsEva SA, a Swiss stock corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser |
|
| January 28, 2022 |
ObsEva Announces Corporate Updates Exhibit 99.1 ObsEva Announces Corporate Updates Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? January 28, 2022 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women?s health, announced today that its board of directors approved on January 28, 2022 an increase of its share capital from |
|
| January 28, 2022 |
6-K 1 d267124d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (A |
|
| January 28, 2022 |
EX-99.2 3 d267124dex992.htm EX-99.2 Exhibit 99.2 AMENDMENT AGREEMENT This Amendment Agreement (the “Agreement”), dated as of January 28, 2022, is made by and between JGB (Cayman) Port Ellen Ltd., in its capacity as Holder, ObsEva SA, a Swiss stock corporation (the “Company”) and each of ObsEva USA Inc., ObsEva Ireland Ltd., and ObsEva Europe B.V., as subsidiary guarantors (collectively, the “Subsi |
|
| January 6, 2022 |
Exhibit 99.1 ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain -Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically si |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execu |
|
| December 17, 2021 |
EX-99.1 2 d275800dex991.htm EX-99.1 Exhibit 99.1 ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids -European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by the U.S. Food and Drug Administration- Ad hoc announcement pursuant to Art. 53 LR of t |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| December 13, 2021 |
6-K 1 d261720d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland ( |
|
| December 13, 2021 |
ObsEva Appoints Will Brown as Chief Financial Officer Exhibit 99.1 ObsEva Appoints Will Brown as Chief Financial Officer Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland ? December 13, 2021 ? ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women?s reproductive health, today announced the appointment of Will Brown as Chief Financial Offi |
|
| December 10, 2021 |
6-K 1 d220661d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland ( |
|
| December 10, 2021 |
Exhibit 99.1 ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021 -Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3 PRIMROSE studies of linzagolix for the treatment of uterine fibroids demonstrating sustained |
|
| November 23, 2021 |
Up to 11,477,396 Common Shares Table of Contents Filed pursuant to Rule 424(b)(7) Registration No. 333-260974 PROSPECTUS Up to 11,477,396 Common Shares This prospectus relates to the resale from time to time of up to 11,477,396 common shares of ObsEva SA, or the Company, by the selling shareholders, including their transferees, pledgees or donees, or their respective successors. We are registering these shares on behalf of the |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| November 22, 2021 |
Exhibit 99.1 Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 ? Obseva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commerciali |
|
| November 22, 2021 |
Obseva Announces Appointment of Stephanie Brown to its Board of Directors Exhibit 99.2 Obseva Announces Appointment of Stephanie Brown to its Board of Directors Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 ? ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women?s reproductive health, today announced that Stephanie Brown has been select |
|
| November 19, 2021 |
Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland November 19, 2021 VIA EDGAR U. |
|
| November 10, 2021 |
Power of Attorney (included on the signature page of the Original Registration Statement). Table of Contents As filed with the Securities and Exchange Commission on November 10, 2021 Registration No. |
|
| November 4, 2021 |
ObsEva Announces Third Quarter 2021 Financial Results and Business Update EX-99.3 4 obsv-ex9937.htm EX-99.3 Exhibit 99.3 ObsEva Announces Third Quarter 2021 Financial Results and Business Update -Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Global License Agreement completed with Organon - - |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| November 4, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a biopharmaceutical company focused on the development and commercialization of novel therapies to improve women?s reproductive health. We are advancing a pipeline of orally-administered innovative new chemical entities, or NCEs, for the treatment of symptoms associated with uterine f |
|
| November 4, 2021 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as at September 30, 2021 and December 31, 2020 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month and nine-month periods ended September 30, 2021 3 Unaudited Condensed Consolidated Statement of Cash Flows for the nine-month perio |
|
| October 29, 2021 |
ObsEva Announces Management Change EX-99.1 2 d250190dex991.htm EX-99.1 Exhibit 99.1 ObsEva Announces Management Change Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 29, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that current Chief Financial Officer |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execu |
|
| October 13, 2021 |
Press Release dated October 13, 2021. Exhibit 99.1 ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids- -Financing agreement with JGB Management to fund the planned launch of linzagolix as well as other development and operational expenses- - Amendment of Kissei exclusive license an |
|
| October 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Addres |
|
| October 13, 2021 |
Exhibit 99.1 ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids- -Financing agreement with JGB Management to fund the planned launch of linzagolix as well as other development and operational expenses- - Amendment of Kissei exclusive license an |
|
| October 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execu |
|
| October 13, 2021 |
Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 12, 2021, between ObsEva SA, a Swiss stock corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set fort |
|
| October 13, 2021 |
EX-99.2 3 d229942dex992.htm EX-99.2 Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 12, 2021, between ObsEva SA, a Swiss stock corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject |
|
| October 13, 2021 |
Exhibit 99.5 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of October 12, 2021 (the ?Execution Date?), is entered into by and between ObsEva SA, a Swiss stock corporation (the ?Company?), and the undersigned purchasers (the ?Purchasers?) identified on the signature pages to that certain Securities Purchase Agreement, by and between the parties hereto |
|
| October 13, 2021 |
Exhibit 99.5 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of October 12, 2021 (the ?Execution Date?), is entered into by and between ObsEva SA, a Swiss stock corporation (the ?Company?), and the undersigned purchasers (the ?Purchasers?) identified on the signature pages to that certain Securities Purchase Agreement, by and between the parties hereto |
|
| August 5, 2021 |
ObsEva Announces Second Quarter 2021 Financial Results and Business Update Exhibit 99.3 ObsEva Announces Second Quarter 2021 Financial Results and Business Update -Linzagolix (Yselty?) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Global License Agreement completed with Organon - -A |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execut |
|
| August 5, 2021 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS EX-99.1 2 obsv-ex9918.htm EX-99.1 Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as at June 30, 2021 and December 31, 2020 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended June 30, 2021 3 Unaudited Condensed Consolidated Statement of Cash Flows f |
|
| August 5, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.2 3 obsv-ex9926.htm EX-99.2 Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a biopharmaceutical company focused on the development and commercialization of novel therapies to improve women’s reproductive health. We are advancing a pipeline of orally-administered innovative new chemical entities, or NCEs, for the treatment of |
|
| July 27, 2021 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| July 27, 2021 |
Exhibit 99.1 Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Ar |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executiv |
|
| June 1, 2021 |
EX-99.1 2 d171886dex991.htm EX-99.1 Exhibit 99.1 ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021 Geneva, Switzerland and Boston, MA – May 31, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that sh |
|
| June 1, 2021 |
EX-99.2 3 d171886dex992.htm EX-99.2 Focused on unmet needs in women’s reproductive health June 2021 Exhibit 99.2 Disclaimer Matters discussed in this presentation may constitute forward-looking statements. The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and |
|
| May 25, 2021 |
ObsEva Announces Proposed Changes to the Composition of its Board of Directors EX-99.1 2 d151415dex991.htm EX-99.1 Exhibit 99.1 ObsEva Announces Proposed Changes to the Composition of its Board of Directors Geneva, Switzerland and Boston, MA – May 25, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that its Board of Directors will propose the electi |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executive |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executive |
|
| May 20, 2021 |
EX-99.1 2 d52708dex991.htm EX-99.1 Exhibit 99.1 ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids -PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment- -Results continue to support the differentiated |
|
| May 6, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executive |
|
| May 6, 2021 |
ObsEva Announces First Quarter 2021 Financial Results and Business Update EX-99.3 4 obsv-ex9936.htm EX-99.3 Exhibit 99.3 ObsEva Announces First Quarter 2021 Financial Results and Business Update -Yselty® for uterine fibroids: US New Drug Application submission planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study pla |
|
| May 6, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise women?s reproductive health. We are advancing a pipeline of orally-administered innovative new chemical entities, or NCEs, for the treatment of sym |
|
| May 6, 2021 |
ObsEva appoints Clive Bertram as Chief Commercial Officer Exhibit 99.1 ObsEva appoints Clive Bertram as Chief Commercial Officer GENEVA, Switzerland and BOSTON, MA ? May 6, 2021 ? ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women?s reproductive health, today announced the appointment of Clive Bertram as Chief Commercial Officer and member of ObsEva?s Executive Committee, effe |
|
| May 6, 2021 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as at March 31, 2021 and December 31, 2020 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month period ended March 31, 2021 3 Unaudited Condensed Consolidated Statement of Cash Flows for the three-month period ended March 31, 2021 |
|
| May 6, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executive |
|
| April 22, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executi |
|
| April 22, 2021 |
ObsEva Annual General Meeting 2021 Exhibit 99.1 ObsEva Annual General Meeting 2021 Geneva, Switzerland and Boston, MA ? April 22, 2021 ? ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women?s reproductive health, today published the invitation to its 2021 Annual General Meeting of Shareholders to be held on May 28, 2021 at 16:30 CEST at the company?s offic |
|
| March 31, 2021 |
EX-99.1 Exhibit 99.1 Focused on unmet needs in women’s reproductive health March 2021Exhibit 99.1 Focused on unmet needs in women’s reproductive health March 2021 Disclaimer Matters discussed in this presentation may constitute forward-looking statements. We expressly disclaim any obligation to update or revise the information herein, The forward-looking statements contained in this presentation r |
|
| March 31, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executi |
|
| March 5, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executi |
|
| March 5, 2021 |
Up to $50,000,000 Common Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233069 PROSPECTUS SUPPLEMENT (to prospectus dated August 14, 2019) Up to $50,000,000 Common Shares We have entered into an open market sale agreement, or sales agreement, with SVB Leerink LLC, or SVB Leerink, relating to common shares of ObsEva SA offered by this prospectus supplement. In accordance with the terms of the sales |
|
| March 5, 2021 |
Current Report of Foreign Issuer - 6-K 6-K 1 d150338d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Add |
|
| March 5, 2021 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of ObsEva SA (the ?Company?) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, David Renas, Chief |
|
| March 5, 2021 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of ObsEva SA (the ?Company?) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Brian O?Callaghan, |
|
| March 5, 2021 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, David Renas, certify that: 1. I have reviewed this annual report on Form 20-F of ObsEva SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 5, 2021 |
ObsEva Announces Year End 2020 Financial Results and Business Update EX-99.1 Exhibit 99.1 ObsEva Announces Year End 2020 Financial Results and Business Update -Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase |
|
| March 5, 2021 |
Sales Agreement, dated March 5, 2021, by and between the Company and SVB Leerink LLC Exhibit 1.1 SALES AGREEMENT March 5, 2021 SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: ObsEva SA, a soci?t? anonyme organized under the laws of Switzerland (the ?Company?), proposes, subject to the terms and conditions stated herein, to sell from time to time through SVB Leerink LLC, as sales agent (the ?Agent?), common shares of the Compan |
|
| March 5, 2021 |
Exhibit 4.16 Loan and Security Agreement among the Registrant, Oxford Finance LLC and ObsEva USA Inc., dated as of August 7, 2019, as amended by the First Amendment to Loan and Security Agreement among the Registrant, Oxford Finance LLC and ObsEva USA Inc., dated as of December 6, 2019 and the Second Amendment to Loan and Security Agreement among the Registrant, Oxford Finance LLC and ObsEva USA I |
|
| March 5, 2021 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Brian O?Callaghan, certify that: 1. I have reviewed this annual report on Form 20-F of ObsEva SA; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit |
|
| March 5, 2021 |
Exhibit 1.1 Statuts de ObsEva SA (ObsEva Ltd) (ObsEva AG) Articles of Association of ObsEva SA (ObsEva Ltd) (ObsEva AG) TITRE I: RAISON SOCIALE ? SIEGE ? BUT ? DUREE TITLE i: CORPORATE NAME ? REGISTERED OFFICE ? PURPOSE ? DURATION Article 1: Raison sociale Article 1: Corporate Name Il existe sous la raison sociale ObsEva SA (ObsEva Ltd) (ObsEva AG) une soci?t? anonyme qui est r?gie par les pr?sent |
|
| March 5, 2021 |
Consent of PricewaterhouseCoopers SA Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-249457, 333-231629 and 333-216170) and Form F-3 (Nos. 333-233069 and 333-221462) of ObsEva SA of our report dated March 5, 2021 relating to the financial statements, which appears in this Form 20-F. /s/ PricewaterhouseCoopers |
|
| March 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* ObsEva SA (Name of Issuer) Common Stock, par value CHF 0.0769 per share (Title of Class of Securities) H5861P103 (CUSIP Number) Nathalie Auber Sofinnova Investments, I |
|
| February 17, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant?s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| February 17, 2021 |
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference EX-99.1 Exhibit 99.1 ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference Geneva, Switzerland and Boston, MA – February 17, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating in a fireside |
|
| February 17, 2021 |
Focused on unmet needs in women?s reproductive health February 2021 Exhibit 99.2 Disclaimer Matters discussed in this presentation may constitute forward-looking statements. The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that ma |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) ObsEva SA (Name of Issuer) Common Shares, par value CHF 1/13 per share (Title of Class of Securities) H5861P103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2021 |
CUSIP No. H5861P103 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 12, 2021 (the “Schedule 13G”), with respect to the Common Stock of ObsEva SA is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, |
|
| February 11, 2021 |
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares EX-99.1 Exhibit 99.1 ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares Geneva, Switzerland and Boston, MA – Thursday 11 February, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pre |
|
| February 11, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* ObsEva SA (Name of Issuer) Common Shares, par value CHF 0.0769 per share (Title of Class of Securities) H5861P103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 11, 2021 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal |
|
| February 11, 2021 |
EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each |
|
| February 10, 2021 |
ObsEva Provides Business Outlook for 2021 EX-99.1 2 d109703dex991.htm EX-99.1 Exhibit 99.1 ObsEva Provides Business Outlook for 2021 GENEVA, Switzerland and BOSTON, MA (February 10, 2021) – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today provided a corporate update, including its roadmap for advancing its clinical programs in 2021 |
|
| February 10, 2021 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal |
|
| January 28, 2021 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal e |
|
| January 28, 2021 |
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares EX-99.1 Exhibit 99.1 ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares Geneva, Switzerland and Boston, MA – Thursday 28 January, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and preg |
|
| January 19, 2021 |
Current Report of Foreign Issuer - 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Addres |
|
| January 19, 2021 |
Corporate Presentation dated January 2021. 1 Focused on unmet needs in women’s reproductive health January 2021 Exhibit 99.1 2 Disclaimer Matters discussed in this presentation may constitute forward-looking statements. The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that |
|
| January 13, 2021 |
EX-99.1 2 obsv-ex991377.htm EX-99.1 1 Focused on unmet needs in women’s reproductive health January 2021 Exhibit 99.1 2 Disclaimer Matters discussed in this presentation may constitute forward-looking statements. The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumption |
|
| January 13, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execu |
|
| January 11, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execu |
|
| January 11, 2021 |
EX-99.1 2 obsv-ex9916.htm EX-99.1 Exhibit 99.1 ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program - European Medicines Agency Validates Yselty MAA for Uterine Fibroids; US NDA Planned for 1H 2021 - Phase 3 EDELWEISS 3 (Conducted in Europe and US) Study of Yselty for Treatment of Endometriosis is Progressing as Planned; Primary Endpoint Readout Expected 4Q 2021 - Phase 3 ED |
|
| January 4, 2021 |
Current Report of Foreign Issuer - 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Addres |
|
| January 4, 2021 |
ObsEva appoints David Renas as Chief Financial Officer Exhibit 99.1 ObsEva appoints David Renas as Chief Financial Officer Geneva, Switzerland and Boston, MA – January 4, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of David Renas as Chief Financial Officer (CFO) and member of the company’s E |
|
| January 4, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2021 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execu |
|
| December 10, 2020 |
EX-99.1 2 obsv-ex9917.htm EX-99.1 Exhibit 99.1 ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids • PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy |
|
| December 10, 2020 |
Yselty? for Uterine Fibroids Clinical Results PRIMROSE 1 up to Week 52 PRIMROSE 2 up to Week 76 10 DEC 2020 Exhibit 99. |
|
| December 10, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| November 24, 2020 |
Exhibit 99.1 ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids • If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: – 100 mg once daily for women with a contraindication to or who prefer to avoid hormonal add |
|
| November 24, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| November 16, 2020 |
PROLONG A phase 2a, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the efficacy, safety and pharmacokinetics of EBOPIPRANT (OBE022) added-on to atosiban, after oral administration in pregnant women with spontaneous preterm labour. |
|
| November 16, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| November 16, 2020 |
Exhibit 99.1 ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor • Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy • Maternal, fetal and neonatal safety comparable to placebo • Data supports advancement of ebopiprant to Phase 2b dose range finding Geneva, Switzerland and Bost |
|
| November 9, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| November 9, 2020 |
ObsEva appoints Brian O’Callaghan as Chief Executive Officer Exhibit 99.1 ObsEva appoints Brian O’Callaghan as Chief Executive Officer Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that ObsEva’s Board of Directors has appointed Brian O’Callaghan, to succeed Dr Ernest |
|
| November 5, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| November 5, 2020 |
ObsEva Announces Third Quarter 2020 Financial Results and Business Update Exhibit 99.3 ObsEva Announces Third Quarter 2020 Financial Results and Business Update – Positive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual Congress - Linzagolix regulatory submissions planned for Q4:20/H1:21 in Europe/U.S. – Actively discussing commercial partnership |
|
| November 5, 2020 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We are focused on providing therapeutic solutions for women between puberty and menopau |
|
| November 5, 2020 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as at September 30, 2020 and December 31, 2019 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month and nine-month periods ended September 30, 2020 3 Unaudited Condensed Consolidated Statement of Cash Flows for the nine-month perio |
|
| October 13, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 13, 2020 Registration No. |
|
| September 14, 2020 |
OBSV / Obseva SA / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 8, 2020 |
EX-1.1 Exhibit 1.1 OBSEVA SA Underwriting and Placement Agency Agreement September 3, 2020 H.C. Wainwright & Co., LLC As Representative of the several Underwriters listed in Schedule 1 hereto and as Placement Agent c/o H.C. Wainwright & Co., LLC 430 Park Avenue New York, NY 10022 Ladies and Gentlemen: ObsEva SA, a société anonyme organized under the laws of Switzerland (the “Company”), proposes to |
|
| September 8, 2020 |
EX-10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Subscription”) is dated as of September 3, 2020, by and between OBSEVA SA, a stock corporation (société anonyme) organized under the laws of Switzerland (the “Company”), and ERNEST LOUMAYE, MD, PHD (the “Investor”). RECITALS A. The Investor wishes to purchase, and the Company wishes to sell, upon the terms and condition |
|
| September 8, 2020 |
EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| September 8, 2020 |
EX-4.1 Exhibit 4.1 COMMON SHARE PURCHASE WARRANT OBSEVA SA Warrant Shares: [ ] Initial Exercise Date: September , 2020 Issue Date: September , 2020 THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| September 8, 2020 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal |
|
| September 8, 2020 |
EX-4.2 Exhibit 4.2 PREFUNDED COMMON SHARE PURCHASE WARRANT OBSEVA SA Warrant Shares: [ ] Initial Exercise Date: September , 2020 Issue Date: September , 2020 THIS PREFUNDED COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| September 8, 2020 |
EX-99.1 Exhibit 99.1 ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company d |
|
| September 8, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-233069 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 14, 2019) 5,490,000 Common Shares Pre-Funded Warrants to Purchase 958,240 Common Shares Warrants to Purchase 6,448,240 Common Shares 958,240 Common Shares Underlying the Pre-Funded Warrants 6,448,240 Common Shares Underlying the Warrants ObsEva SA We are offering ( |
|
| August 14, 2020 |
EX-99.1 Focused on unmet needs in women’s reproductive health August 2020 Exhibit 99.1 Disclaimer Matters discussed in this presentation may constitute forward-looking statements. The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances t |
|
| August 14, 2020 |
Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal ex |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal execut |
|
| August 6, 2020 |
ObsEva Announces Second Quarter 2020 Financial Results and Business Update Exhibit 99.3 ObsEva Announces Second Quarter 2020 Financial Results and Business Update – Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids – Phase 3 data from PRIMROSE 2 trial demonstrated sustained efficacy and continued safety over 52 weeks of treatment with linzagolix, including bone mineral density |
|
| August 6, 2020 |
OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 OBSEVA SA INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Condensed Consolidated Balance Sheets as at June 30, 2020 and December 31, 2019 2 Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended June 30, 2020 3 Unaudited Condensed Consolidated Statement of Cash Flows for the six-month period ended June |
|
| August 6, 2020 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We are focused on providing therapeutic solutions for women between puberty and menopau |
|
| July 7, 2020 |
EX-99.1 Exhibit 99.1 Phase PRIMROSE 3 Trial 1 and Results 2 DESIGNED TO TREAT MORE WOMEN SUFFERING FROM UTERINE FIBROIDS Yselty®, our proposed trade name for linzagolix, is conditionally acceptable for the FDA. Linzagolix has not been approved by FDA for any indication for use. Linzagolix is an investigational drug. Disclaimer Matters discussed in this presentation may constitute forward-looking s |
|
| July 7, 2020 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal exec |
|
| July 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executiv |
|
| July 6, 2020 |
Exhibit 99.1 ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids • PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 • PRIMROSE 2 results demonstrate sustained efficacy and continued safety of linzagolix at week 52 • Results con |
|
| July 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2020 Commission File Number: 001-37993 OBSEVA SA (Translation of registrant’s name into English) Chemin des Aulx, 12 1228 Plan-les-Ouates Geneva, Switzerland (Address of principal executiv |
